Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 3/2015

01.03.2015 | Breast Cancer (B Overmoyer, Section Editor)

Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy

verfasst von: Sausan Abouharb, Stacy Moulder

Erschienen in: Current Oncology Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Metaplastic breast cancer is a rare subtype of invasive mammary carcinoma, with an aggressive behavior and usually poor outcome. Responses to systemic chemotherapy are suboptimal compared to patients with standard invasive ductal carcinoma. Limited data are available in regards to best treatment modalities, including chemotherapy. This review gives an overview of metaplastic breast cancer and its clinical and pathologic characteristics, in addition to treatment strategies, clinical trials, and future directions.
Literatur
1.
Gogas J, Kouskos E, Markopoulos C, Mantas D, Antonopoulou Z, Kontzoglou K, et al. Carcinosarcoma of the breast: report of two cases. Eur J Gynaecol Oncol. 2003;24(1):93–5.PubMed
2.
3.
4.
Wada H, Enomoto T, Tsujimoto M, Nomura T, Murata Y, Shroyer KR. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol. 1998;29(11):1324–8.CrossRefPubMed
5.
Foschini MP, Dina RE, Eusebi V. Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomas. Semin Diagn Pathol. 1993;10(2):128–36.PubMed
6.
Bocker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 2002;86:116–9.PubMed
7.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471–8. doi:10.​1007/​s10549-011-1359-8.CrossRefPubMed
8.
9.
Stanley MW, Tani EM, Skoog L. Metaplastic carcinoma of the breast: fine-needle aspiration cytology of seven cases. Diagn Cytopathol. 1989;5(1):22–8.CrossRefPubMed
10.
11.
12.•
Leddy R, Irshad A, Rumboldt T, Cluver A, Campbell A, Ackerman S. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features. J Clin Imaging Sci. 2012;2:21. doi:10.​4103/​2156-7514.​95435. Pathologic and imaging findings that physicians should be aware of to recognize metaplastic breast cancer.CrossRefPubMedCentralPubMed
13.•
Choi BB, Shu KS. Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment. Acta Radiol. 2012;53(1):5–11. doi:10.​1258/​ar.​2011.​110341. Imaging and pathologic factors to be considered in the diagnosis of metaplastic breast cancer that should alert oncologists.CrossRefPubMed
14.
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73. doi:10.​1245/​s10434-006-9124-7.CrossRefPubMed
15.••
Song Y, Liu X, Zhang G, Song H, Ren Y, He X, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013;11:129. doi:10.​1186/​1477-7819-11-129. Comparison between clinicopathological features and outcomes of metaplastic breast carcinoma and invasive ductal carcinoma, showing a poorer outcome in metaplastic breast carcinoma.CrossRefPubMedCentralPubMed
16.
Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB)—a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013;22(5):968–73. doi:10.​1016/​j.​breast.​2013.​05.​010.CrossRefPubMed
17.
Kuo SH, Chen CL, Huang CS, Cheng AL. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer. Anticancer Res. 2000;20(3B):2219–22.PubMed
18.
19.
Santiago Perez JT, Perez Vazquez MR, Rivera Valdespino Ade L, Gil Valdes D. Carcinosarcoma of the breast: a tumour with controversial histogenesis. Clin Transl Oncol. 2005;7(6):255–7.CrossRefPubMed
20.
Teixeira MR, Qvist H, Bohler PJ, Pandis N, Heim S. Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes, Chromosomes Cancer. 1998;22(2):145–51.CrossRefPubMed
21.
22.••
Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol. 2013;2(1):31. doi:10.​1186/​2162-3619-2-31. A great updated overview of Metaplastic Breast Cancer.CrossRefPubMedCentralPubMed
23.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20(7):628–35.CrossRefPubMed
24.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer. 1990;65(2):272–6.CrossRefPubMed
25.
Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20(8):732–40.CrossRefPubMed
26.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21(11):1142–50.CrossRefPubMed
27.
Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol. 1987;11(12):918–29.CrossRefPubMed
28.
Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 1999;85(10):2170–82.CrossRefPubMed
29.
30.
Sanguinetti A, Lucchini R, Santoprete S, Farabi R, Fioriti L, Bistoni G et al. Metaplastic carcinoma of the breast treatment, results and prognostic factors based on international literature. Ann Ital Chir. 2013; 84.
31.
Esbah O, Turkoz FP, Turker I, Durnali A, Ekinci AS, Bal O, et al. Metaplastic breast carcinoma: case series and review of the literature. Asian Pac J Cancer Prev. 2012;13(9):4645–9.CrossRefPubMed
32.
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9.CrossRefPubMed
33.
34.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64(7):1490–9.CrossRefPubMed
35.
Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120(3):627–37. doi:10.​1007/​s10549-010-0780-8.CrossRefPubMed
36.
Lester TR, Hunt KK, Nayeemuddin KM, Bassett Jr RL, Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012;131(1):41–8. doi:10.​1007/​s10549-011-1393-6.CrossRefPubMed
37.
Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349–53. doi:10.​1007/​s10549-006-9301-1.CrossRefPubMed
38.
39.
40.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32. doi:10.​1056/​NEJMoa020989.CrossRefPubMed
41.
Jacobson JA, Danforth DN, Cowan KH, D’Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. New England J Med. 1995;332(14):907–11. doi:10.​1056/​NEJM199504063321​402.CrossRef
42.•
Hu Q, Chen WX, Zhong SL, Li J, Luo Z, Tang JH, et al. Current progress in the treatment of metaplastic breast carcinoma. Asian Pac J Cancer Prev. 2013;14(11):6221–5. Review of current multimodality treatment recommendations of metaplastic breast cancer.CrossRefPubMed
43.
Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. 1999;71(4):220–5.CrossRefPubMed
44.
45.
46.
Gultekin M, Eren G, Babacan T, Yildiz F, Altundag K, Guler N, et al. Metaplastic breast carcinoma: a heterogeneous disease. Asian Pac J Cancer Prev. 2014;15(6):2851–6.CrossRefPubMed
47.••
Nowara E, Drosik A, Samborska-Plewicka M, Nowara EM, Stanek-Widera A. Metaplastic breast carcinomas - analysis of prognostic factors in a case series. Contemp Oncol. 2014;18(2):116–9. doi:10.​5114/​wo.​2014.​41392. Single institution case series with review of outcomes, treatment modalities, and pathologic findings.
48.
49.
Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26(57):7859–71. doi:10.​1038/​sj.​onc.​1210593.CrossRefPubMed
50.
51.
52.
Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107(35):15449–54. doi:10.​1073/​pnas.​1004900107.CrossRefPubMedCentralPubMed
53.
54.
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(5):R68. doi: 10.​1186/​bcr2635.
55.
Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 29(19):e572-5. doi: 10.​1200/​JCO.​2010.​34.​0604.
Metadaten
Titel
Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy
verfasst von
Sausan Abouharb
Stacy Moulder
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 3/2015
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0431-z

Weitere Artikel der Ausgabe 3/2015

Current Oncology Reports 3/2015 Zur Ausgabe

Gynecologic Cancers (NS Reed, Section Editor)

Long-Term Experience with (Laterally) Extended Endopelvic Resection (LEER) in Relapsed Pelvic Malignancies

Head and Neck Cancers (E Hanna, Section Editor)

Surgical Salvage of Recurrent Nasopharyngeal Carcinoma

Gastrointestinal Cancers (BG Czito, Section Editor)

The Neoadjuvant Treatment of Rectal Cancer: A Review

Pediatric Oncology (S Epelman, Section Editor)

Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors

Head and Neck Cancers (E Hanna, Section Editor)

The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Squamous Cell Carcinoma: a Current Review

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise